The 2025 Creating a Scientific Superpower conference builds on last year's success by bringing together top minds to advance the UK's position as a global scientific leader. This one-day event will feature discussions, networking, and insights on building a competitive innovation ecosystem.
Guest blog by Nick Hutchinson, Associate Vice President Business Development, Just - Evotec Biologics
Ballroom J.POD® Redmond, WA. Just – Evotec Biologics
PR and Communications Manager
Full time
Reports to: Head of Marketing and Communications
Job location: Xampla HQ, Cambridge Science Park (hybrid)
Introduction to Xampla
Xampla is a groundbreaking materials technology company unlocking the power of natural plant polymers for a range of industries and applications, from plastic-free alternatives in packaging to high-performance encapsulation.
Working with leading research institutions, Amsbio has established itself as a premier supplier of high quality Heparan Sulfate (HS) monoclonal antibodies driving breakthroughs in Glycobiology research.
Cambridge, UK, 10 April 2025: Source BioScience UK Ltd, an industry-leading provider of genomic services and histopathology diagnostics, today announced it had completed the acquisition of Cambridge Clinical Laboratories (CCL), a leading Cambridge-based provider of clinical, personalised healthcare testing services. The acquisition bolsters the Company’s clinical diagnostics portfolio by leveraging the expertise of the CCL team and new state-of-the-art clinical lab facilities at Vision Park in Cambridge, providing streamlined testing services for both preclinical and clinical research.
London, April 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for iOnctura and is pleased to announce the placement of Dr. Mark Velleca as Chair of the Board of Directors.
iOnctura is a clinical-stage precision oncology company combating neglected and hard-to-treat cancers with a pipeline of first-in-class small molecules.
BioBeat25 13.30-18.00, Thursday 8 May at the Cambridge Union is all about getting ahead of the curve in biotech!
There are two fantastic panels on upcoming key technologies and partnering hotspots and getting to closure on investment deals.
The first on Biotech and Partnering Hotspots will explore key areas where partnerships tend to be struck and the drivers behind such deals.
Howard Group strengthens its South Cambridge science and healthcare ecosystem with latest signing
Cancer Research Horizons, the innovation arm of Cancer Research UK, has announced a collaboration with Histofy, a leader in AI-driven histopathology solutions, to develop tools that predict how colorectal cancer patients respond to different treatment options using the multi-modal S:CORT dataset.
Research and development innovation is the lifeblood of the pharmaceutical sector but in a highly competitive market returns are hard won. Our 15th annual detailed analysis, in Measuring the return from pharmaceutical innovation: Be brave, be bold, shows an upward trajectory with the IRR increasing from 4.3% in 2023 to 5.9% in 2024. This positive trend is driven largely by new high-value blockbuster assets entering the late-stage pipeline, particularly for therapies addressing obesity, menopause, Alzheimer’s, and other unmet needs.